Q1 2019 Immunovia AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the Immunovia Q1 Report 2019. Today, I am pleased to present CEO, Mats Grahn. (Operator Instructions) Mats, please begin.
()-
Thank you, and welcome everybody. We will, of course, cover Q1, but most of the time, I'll spend on the status of the optimization work that is on schedule as you may have seen on today's press release.
However, I'll start with some words about the quarter 1 report. And looking at the finances there, we do have increased the costs and according to our plans, that is dependent on organizational enlargement, marketing activities that is accelerating and also, of course, the prospective studies that are growing and moving forward.
At the end of the quarter, we had SEK 360 million at hand, so we are well funded for the upcoming 2 years.
Other highlights of the quarter 1 is that we do, during the quarter, increased our focus on the Investor Relations by engaging our Investor Relations Director, Julie Silber, and for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |